Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | CBLB | Q13191 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244383 | 0.88 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL3244258 | 0.83 | HDAC4 (0.37) | — | |
| SCHEMBL3242226 | 0.82 | PIK3CD (0.33) | PIK3CDPIK3CAPIK3CGRIPK1 | |
| SCHEMBL3248775 | 0.75 | SCN9A (0.33) | — | |
| SCHEMBL3242312 | 0.67 | BACE1 (0.33) | PIK3CDPIK3CAPIK3CG | |
| SCHEMBL3358047 | 0.66 | BACE1 (0.46) | — | |
| SCHEMBL3239041 | 0.63 | BACE1 (0.36) | — | |
| SCHEMBL3242222 | 0.62 | BACE1 (0.44) | KMT2APIK3CDPIK3CAPIK3CG | |
| SCHEMBL15063694 | 0.53 | ESR1 (0.41) | MEN1KMT2ALMNATP53 | |
| SCHEMBL27517722 | 0.53 | DHFR (0.51) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125087-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056195-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125081-A1 | NEW COMPOUNDS 574 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056194-A1 | 5H-PYRROLO [ 3, 4-B] PYRIDIN DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125081-A1 | NEW COMPOUNDS 574 | PSEN1, PSEN2, BACE1 | MEN1 2636/4885KMT2A 3762/4885PIK3CD 540/4885 |
| US-20100125087-A1 | NEW COMPOUNDS 575 | PSEN1, PSEN2, BACE1 | MEN1 2423/4885KMT2A 3888/4885PIK3CD 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.